100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
325471-28-1Tert-Butyl (3S,5S)-6-Chloro-3,5-dihydroxyhexanoate
● In Stock
| Catalogue No.: | VE008980 |
|---|---|
| CAS No.: | 325471-28-1 |
| Mol. Formula: | C10H19ClO4 |
| Mol. Weight: | 238.71 g/mol |
Additional information on CAS 325471-28-1
Parent drug
RosuvastatinIUPAC Name
(3S, 5S)-tert-Butyl 6-chloro-3, 5-dihydroxyhexanoateSynonyms
N/ADescription
It is certain distinct pharmacologic and pharmacokinetic characteristics. It has significant LDL-C lowering potential, the minimal potential for CYP3A4 interactions, and low extrahepatic tissue penetration. A completely synthesized HMG-CoA reductase inhibitor is rosuvastatin. Other HMG-CoA reductase inhibitors are either synthetically made from heptanoic acid or naturally produced from mevalonic acid. A novel class of 3, 5-dihydroxy-heptanoate and N-methane sulfonyl pyrrole-substituted methane sulphonamide pyrimidines include rosuvastatin. Rosuvastatin selectively and permanently inhibits HMG-CoA reductase by competitive inhibition. In the cholesterol biosynthetic route, this enzyme transforms HMG-CoA into mevalonic acid, which is the rate-limiting step in cholesterol production.References
Luvai, Ahai, et al. “Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease.†Clinical Medicine Insights: Cardiology, vol. 6, Jan. 2012, p. CMC.S4324, https://doi.org/10.4137/cmc.s4324. ‌Request a Quote
"*" indicates required fields
Other products related to Rosuvastatin impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
Rosuvastatin
CAS No. 154026-93-4
Cat No. VE008578